[
  {
    "ts": null,
    "headline": "Anavex Life Sciences: Inching Closer To Binary Regulatory Outcome In The EU",
    "summary": "Anavex (AVXL) awaits a key EU ruling on its Alzheimerâs drug. Learn about trial challenges, approval risks, and why a Sell rating is advised.",
    "url": "https://finnhub.io/api/news?id=9b14383517a596c19d1c826771b161eb68042b8d9a20c85a762da0da49c4c4f1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762256639,
      "headline": "Anavex Life Sciences: Inching Closer To Binary Regulatory Outcome In The EU",
      "id": 137315657,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1383032509/image_1383032509.jpg?io=getty-c-w1536",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Anavex (AVXL) awaits a key EU ruling on its Alzheimerâs drug. Learn about trial challenges, approval risks, and why a Sell rating is advised.",
      "url": "https://finnhub.io/api/news?id=9b14383517a596c19d1c826771b161eb68042b8d9a20c85a762da0da49c4c4f1"
    }
  }
]